RV 001 - RhoVac

Drug Profile

RV 001 - RhoVac

Alternative Names: RV 001 - RhoVac; RV 001V; RV001V - RhoVac

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RhoVac
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 19 Feb 2018 RhoVac completes phase I/II trial in Prostate cancer in Denmark
  • 30 Mar 2017 Phase-I/II clinical trials in Prostate cancer in Denmark (SC) (NCT03199872)
  • 03 Nov 2016 RhoVac plans a phase IIb trial for cancer (in ex-non small cell lung cancer) (RhoVac website, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top